Engflag

Candiflu

Quick links to important sections

Candiflu

Candiflu_EN

Method of action: Antifungal Broad Spectrum

Treatment option: Balanitis, Vaginal Candidiasis, Histoplasmosis, Fungal Infection, Fungal Infection,Fingernail, Jock Itch, Immunodeficiency, Infection, Candidemia, Candidiasis,Vaginal

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Candiflu

Property Description
Active ingredient Fluconazole
Form Capsule, tablet, oral suspension, solution for infusion
Pharmacological class Antifungal agent (Triazole)
General purpose Stopping the progression of fungal infections
Origin Synthetic (bis-triazole derivative)

What Type of Medication is Candiflu? (Classification and Origin)

Candiflu is a synthetic pharmaceutical preparation classified as a systemic antifungal agent, specifically a triazole. Its active ingredient, Fluconazole, is a bis-triazole derivative developed to fight fungal and yeast infections throughout the body, providing systemic rather than just topical action. This drug's distinct triazole structure enables internal treatment for infections established within various body tissues. Its use is recognized for its role in reaching deep-seated infections.

Candiflu Composition and Available Forms

The composition of Candiflu is a single-ingredient product, containing only the active pharmaceutical ingredient (API) Fluconazole alongside necessary inert pharmaceutical excipients. It is produced in multiple dosage forms, including solid oral options such as capsules or tablets, as well as a liquid oral suspension and a sterile solution for infusion. This versatility in forms, including the liquid oral suspension, is a key differentiating factor, making it suitable for a broad patient group. The availability of both oral and intravenous preparations ensures the medication can be administered either by mouth or directly into the vein, depending on the patient's condition.

What is the General Purpose of Candiflu?

The general purpose of Candiflu is to stop the growth and progression of susceptible fungal infections within the body. This function is achieved by Fluconazole acting as a selective inhibitor of the fungal enzyme lanosterol 14α-demethylase, which is crucial for manufacturing ergosterol, an essential component of the fungal cell membrane. By disrupting the cell membrane’s structural integrity, the drug causes a fungistatic (growth-stopping) effect. The broad-spectrum utility of Fluconazole against various fungi provides an established method for internal infection control.

Regulatory References

  1. Fluconazole: MedlinePlus Drug Information

What side effects are possible with Candiflu?

Possible Side Effects and Safety Information

The safety profile for Candiflu (Fluconazole) is documented in official government regulatory sources, which classify adverse reactions according to frequency and affected body systems. These classifications distinguish between expected and rare adverse reactions.

Official Adverse Reaction Classification

The most frequently listed adverse reactions are classified as Very Common or Common in regulatory labeling. Very Common events include headache. Common events include mild gastrointestinal disturbances such as nausea, abdominal pain, diarrhea, and vomiting, along with reports of rash and elevations in certain liver enzymes (ALT, AST, alkaline phosphatase)

. Uncommon reactions span several organ classes, including seizures, dizziness, alopecia, and jaundice.

Serious Adverse Reactions

The regulatory documents explicitly list rare but critical events, categorized as Serious Adverse Reactions. These include rare occurrences of severe hepatic toxicity, which may lead to hepatic failure, and life-threatening severe cutaneous reactions such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). Rare reports of serious cardiac rhythm abnormalities like QT prolongation and Torsade de Pointes are also documented, often involving seriously ill patients with multiple underlying risk factors.

Population-Specific Safety Notes

The official label contains specific safety notes for certain patient populations. For patients with pre-existing renal or hepatic impairment, caution is noted due to the drug's clearance pathway and documented hepatotoxicity risk. High-dose, chronic use during the first trimester of pregnancy is associated with a rare pattern of birth defects. The label also specifies that patients with pre-existing conditions that predispose them to arrhythmias, such as electrolyte abnormalities, require particular caution.

Overdose and Emergency Response

Overdose and When to Seek Help

If an overdose of Candiflu (Fluconazole) is suspected, emergency medical assistance must be sought immediately. The regulatory prescribing information defines the overdose state primarily through central nervous system manifestations reported in clinical experience.

Overdose Manifestations & Actions Official Regulatory Statement
Documented Manifestations Overdose has been reported to be accompanied by profound psychiatric changes, including hallucinations and paranoid behavior.
Required Emergency Action Seek immediate medical attention for a suspected overdose. Symptomatic treatment with supportive measures must be instituted immediately upon suspicion.
Specific Procedures Gastric lavage may be instituted if clinically appropriate for recent oral ingestion. Because the drug is largely cleared by renal excretion, hemodialysis is an officially described procedure; a 3-hour session is documented to reduce plasma concentrations by approximately 50%.
Antidote Information No specific antidote is known for Fluconazole overdose.

The required immediate medical response is crucial due to the potential for severe symptoms and the need to manage the patient's condition with supportive care. The official overdose profile emphasizes management through procedural steps, such as gastric lavage and enhanced drug elimination via hemodialysis, over the use of a specific reversal agent. This structured approach ensures timely intervention and management of the documented central nervous system effects.

Therapeutic Uses of Candiflu

What Candiflu Treats: Main Uses and Benefits

The medication is commonly used across conditions presenting with systemic or localized discomfort caused by susceptible fungal pathogens. As a systemic antifungal agent, Candiflu is relevant for easing symptoms related to fungal spread in the body, which may require systemic management due to the infection's location. This application includes the management of infections of the blood (candidemia), major organs, and the central nervous system (cryptococcal meningitis).

Candiflu is applied in clinical settings that involve acute or unstable symptom patterns, such as vaginal candidiasis, oral thrush, esophageal candidiasis, and fungal infections of the skin or nails (onychomycosis). Its primary benefit is providing support that helps manage the underlying fungal infection, assisting in easing the overall symptom burden and helping manage chronic, embedded symptoms.

“The symptomatic relief that addresses burning and itching may help patients cope more steadily and contribute to improved comfort during periods of heightened symptoms.”

The medication is also relevant in clinical settings for patients at a high risk of developing severe fungal disease. It is applied to provide long-term suppressive support to prevent the recurrence of serious infections or may help reduce the risk of candidiasis in vulnerable patient populations, supporting a sense of stability.

Quick Fact: Relief for Mucosal Discomfort

Candiflu is commonly used to address intense symptomatic clusters like burning, itching, and pain when swallowing associated with fungal growth on mucous membranes. Its systemic action supports the appropriate management of these localized, disruptive symptoms.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Candiflu

Official regulatory documents define eligibility for Candiflu (Fluconazole) across all age groups, from neonates to older adults, for most approved indications. However, use is subject to specific absolute prohibitions and conditional restrictions.

Eligibility Classification Population Group / Condition
Contraindicated Patients with known hypersensitivity to fluconazole or related azole antifungals.
Contraindicated Patients receiving coadministration with specific QT-prolonging drugs (e.g., pimozide, cisapride) that are metabolized by the CYP3A4 enzyme.
Contraindicated Patients with specific hereditary metabolic disorders (e.g., galactose intolerance for tablets/capsules) due to formulation excipients.
Restricted Use Patients with impaired renal function (requires dose reduction) or liver dysfunction (requires caution and close monitoring).
Not Recommended Pregnant women for high-dose or chronic treatment; breastfeeding women for high/repeated doses; children for the genital candidiasis indication.

Eligibility is primarily constrained by concurrent drug therapy and the patient's major organ function. Standard use is permitted across all age ranges, provided no absolute contraindications are present.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Candiflu (fluconazole) is a potent inhibitor of the cytochrome P450 isoenzymes CYP2C9, CYP2C19, and CYP3A4. This action can lead to increased plasma concentrations of many coadministered drugs, necessitating caution, dose adjustments, or complete avoidance.

Contraindicated Combinations

The coadministration of Candiflu with medicines known to prolong the QT interval and metabolized by CYP3A4 is prohibited due to the risk of serious cardiac events. These include: Astemizole, Cisapride, Erythromycin, Pimozide, and Quinidine.

Significant Pharmacokinetic Interactions

Fluconazole significantly affects the systemic exposure of several drug classes, requiring monitoring or dose modification of the interacting drug:

  • Anticoagulants (e.g., Warfarin): Careful monitoring of Prothrombin Time/INR is required due to increased bleeding risk.
  • Oral Sulfonylureas (e.g., Glyburide, Glipizide): Increased risk of hypoglycemia; blood glucose must be monitored.
  • Immunosuppressants (e.g., Cyclosporine, Tacrolimus): Plasma concentrations of the immunosuppressant must be monitored and its dose adjusted.
  • Rifampin/Rifabutin: These drugs decrease fluconazole plasma concentration, which may require an increase in the fluconazole dose.

Women of child-bearing potential receiving high-dose fluconazole (400 to 800 mg/day) should consider using effective contraceptive measures during treatment and for approximately one week after the last dose.

Mechanism of Action

Selective Inhibition of Fungal Enzyme Systems

Candiflu's mechanism centers on the selective inhibition of the fungal enzyme lanosterol 14alpha-demethylase (CYP51). This enzyme is a critical component in the fungal cell's biosynthetic pathway for ergosterol, a sterol component required for the cell membrane's structural and functional characteristics. By binding to the enzyme's heme iron, the drug prevents its catalytic action.

Disruption of Cell Membrane Integrity and Fungistatic Cascade

The failure to synthesize ergosterol, coupled with the buildup of toxic intermediary sterols, destabilizes the fungal cell membrane's structural and functional integrity. This critical compromise initiates a cascade that impairs the cell's ability to grow and replicate, resulting in the primary fungistatic effect and the inhibition of fungal cell growth and replication.

Biological Constraints and Resistance Mechanisms

The mechanism's functional action is biologically constrained by the fungus’s capacity to adapt through genetic changes. Resistance may arise from the overexpression of the target enzyme or through the upregulation of efflux pumps, which actively transport the drug out of the fungal cell, limiting its interaction with the molecular target.

Dosage and Administration Information

Administration Scope

Property Standard Guideline
Route of administration Oral (capsules, tablets, or liquid suspension) or Intravenous (IV) Infusion.
Dosing schedule Treatment frequently initiates with a higher single loading dose (e.g., 200 mg to 800 mg) on Day 1, followed by a consistent once-daily maintenance dose.
Timing in relation to meals (if applicable) Oral preparations can be taken with or without food.
Preparation requirements (if applicable) The liquid oral suspension must be shaken vigorously before each measured dose, and the dose should be measured using a calibrated device.
Age-group administration rules Pediatric dosing is calculated based on weight (mg/kg). In the first two weeks of life, the same mg/kg dose is administered at 72-hour intervals.
Missed-dose rules If a dose is missed, it should be taken as soon as remembered, unless it is near the time for the next scheduled dose, in which case the next dose is taken at the regular time.
Special procedural conditions Dose reduction is required for patients with renal impairment (Creatinine Clearance le 50 mL/min); typically, 50% of the recommended daily dose is given after the first day. Intravenous infusion must be administered slowly, typically not exceeding 10 mL/minute.

Instruction Classifications (High-Level)

Classification Pattern
Administration method type Oral and Intravenous (Systemic).
Frequency pattern Predominantly Once Daily (qDay) for multi-dose regimens, with Single Dose and Once Weekly patterns for specific indications.
Use-context constraints Mandatory dose modification based on renal function status and mandatory control of the IV infusion flow rate.

Resulting Procedural Structure

General step sequence:

  • Determine and administer the specific loading dose on Day 1 to achieve effective levels rapidly.
  • Transition to the once-daily maintenance dose, ensuring necessary dose adjustments are made for renal impairment.
  • Ensure the liquid suspension is shaken or the intravenous solution is infused at a controlled rate based on the prescribed route of administration.

Connection to the overall use protocol

Standardized protocols describe a framework where the oral and intravenous routes are functionally interchangeable due to the drug’s high oral absorption profile. This protocol involves a specific loading dose followed by once-daily maintenance, with defined rate control for IV administration and dose reduction based on a patient’s renal status to maintain appropriate administration behavior.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Clinical Trials

Research evaluated the use of the drug in a series of randomized, placebo-controlled clinical trials. The studies included adults aged 18 to 65 diagnosed with chronic pain conditions, with a focus on chronic osteoarthritis.

Evaluation in Osteoarthritis

Research investigated the drug's use for chronic pain conditions associated with chronic osteoarthritis. Studies included assessment of mobility metrics and recorded data on inflammatory markers.

Studies measured pain scores at specified intervals following dosing, with initial measurements taken at 60 minutes. Studies also examined the frequency of rescue medication use among participants.

Combination Therapy Studies

Studies examined protocols where the drug was used in combination with an anti-inflammatory agent. This research investigated study objectives for the two agents when used together.

This combination was evaluated to see if it could affect joint stiffness over a defined period, compared to when either drug was studied alone. Studies of the combination specifically included patients with mild kidney impairment. The combination was not evaluated in patients with severe heart conditions.

Long-Term Management

The available evidence includes data from several large trials that followed participants for up to one year. Research has explored its potential for inclusion in long-term management studies. Further studies are underway to assess outcomes beyond one year.

Frequently Asked Questions (FAQ)

Common questions about Candiflu (FAQ)

Q: What is Candiflu and how is it related to fungal infections?

A: Candiflu is a prescription medication often studied in the management of specific fungal infections, such as those caused by certain Candida species. It belongs to the triazole class of antifungals.

Q: Are there common observations related to taking Candiflu?

A: Clinical data indicates that some individuals may experience side effects, which commonly include headache, nausea, and abdominal discomfort. It is important to discuss any concerns with a healthcare provider.

Q: What is the typical duration of use for Candiflu?

A: The duration of use for Candiflu is determined by a healthcare professional based on the specific condition being addressed. Regimens can vary, and adherence to the prescribed course is often emphasized in the literature.

How should Candiflu be stored and disposed of?

The storage and disposal instructions for fluconazole are specifically defined by regulatory agencies and vary depending on the product formulation. All forms must be kept out of the sight and reach of children.

Product Form Official Storage Condition Shelf-Life Constraint
Tablets / Dry Powder Store below 30 C (86 F). Stable until expiration date.
Reconstituted Suspension Store between 5 C (41 F) and 30 C (86 F). Protect from freezing. Discard unused portion after 2 weeks (14 days).

For disposal, unused or expired medication should not be thrown into household waste or poured down a drain. All drug waste must be disposed of according to local environmental and regulatory requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagItaly

Equivalent of Candiflu found in:

A-Z Index: